<div id="readability-page-1">On April 2, 2026, in Delray Beach, Florida, PanGIA Biotech, Inc. unveiled significant findings from a peer-reviewed clinical study titled &#34;Urine-Based Machine Learning Assay Detects Prostate Cancer&#34; published in Diagnostics. The study showcased the clinical efficacy of PanGIA Analysis System (PAS) in detecting prostate cancer with remarkable accuracy. The research underscores the potential of PAS to revolutionize prostate cancer diagnosis and treatment.</div>

PRTG

SBIO

LABU

IBBQ

<p>PanGIA Biotech, Inc. announced a peer-reviewed study published in Diagnostics demonstrating its PanGIA Analysis System's 97.8% sensitivity in detecting prostate cancer using a urine-based liquid biopsy powered by machine learning. The study evaluated 283 participants and showed high specificity for high-grade cancers. This innovative approach aims to reduce unnecessary surgical biopsies and supports earlier clinical decision-making. The findings validate PanGIA's platform for broader applications in cancer detection, emphasizing the use of complex biochemical patterns rather than single biomarkers.</p>

Unusual Whales

Portage Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

PanGIA Biotech Announces Peer-Reviewed Study in Diagnostics Showing 97.8% Sensitivity in Detecting Prostate Cancer Using a Urine-Based Liquid Biopsy with Machine Learning